Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anita Mamtani

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Annual Review of Medicine|August 31, 2016
Why Are There So Many Mastectomies in the United States?Anita Mamtani, Monica Morrow
Oncology (Williston Park, N.Y.)|March 21, 2025
Updates in Surgical Management of the AxillaAnita Mamtani, Andrea V Barrio
Surgical Oncology Clinics of North America|November 15, 2017
Lobular Breast Cancer: Different Disease, Different Algorithms?Anita Mamtani, Tari A King
Current Breast Cancer Reports|February 8, 2021
Treatment of Ductal Carcinoma in Situ: Considerations for Tailoring Therapy in the Contemporary EraAnita Mamtani, Kimberly J Van Zee
Clinical Case Reports|May 19, 2016
Diabetes insipidus uncovered during conservative management of complicated acute appendicitisAnita Mamtani, Stephen R Odom, Kathryn L Butler
Annals of Surgical Oncology|April 22, 2017
Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast CancerAnita Mamtani, Sujata Patil, Michelle Stempel, et al.
Annals of Surgical Oncology|September 15, 2021
Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast CancersAnita Mamtani, Varadan Sevilimedu, Alain Vincent, et al.
Cancer|March 24, 2017
Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?Anita Mamtani, Sujata Patil, Michelle M Stempel, et al.
American Journal of Surgery|July 6, 2019
Unplanned readmissions following breast cancer surgeryTed A James, Gyulnara Kasumova, Amuyla Alapati, et al.
Breast Cancer Research and Treatment|July 28, 2025
Axillary dissection is avoidable in most cT1N0 triple-negative & HER2+ breast cancers treated with upfront surgeryAnita Mamtani, Varadan Sevilimedu, Andrea V Barrio, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Annual Review of Medicine|August 31, 2016
Why Are There So Many Mastectomies in the United States?Anita Mamtani, Monica Morrow
Oncology (Williston Park, N.Y.)|March 21, 2025
Updates in Surgical Management of the AxillaAnita Mamtani, Andrea V Barrio
Surgical Oncology Clinics of North America|November 15, 2017
Lobular Breast Cancer: Different Disease, Different Algorithms?Anita Mamtani, Tari A King
Current Breast Cancer Reports|February 8, 2021
Treatment of Ductal Carcinoma in Situ: Considerations for Tailoring Therapy in the Contemporary EraAnita Mamtani, Kimberly J Van Zee
Clinical Case Reports|May 19, 2016
Diabetes insipidus uncovered during conservative management of complicated acute appendicitisAnita Mamtani, Stephen R Odom, Kathryn L Butler
Annals of Surgical Oncology|April 22, 2017
Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast CancerAnita Mamtani, Sujata Patil, Michelle Stempel, et al.
Annals of Surgical Oncology|September 15, 2021
Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast CancersAnita Mamtani, Varadan Sevilimedu, Alain Vincent, et al.
Cancer|March 24, 2017
Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?Anita Mamtani, Sujata Patil, Michelle M Stempel, et al.
American Journal of Surgery|July 6, 2019
Unplanned readmissions following breast cancer surgeryTed A James, Gyulnara Kasumova, Amuyla Alapati, et al.
Breast Cancer Research and Treatment|July 28, 2025
Axillary dissection is avoidable in most cT1N0 triple-negative & HER2+ breast cancers treated with upfront surgeryAnita Mamtani, Varadan Sevilimedu, Andrea V Barrio, et al.
Pageof 5